Anti-Interleukin 17A Biologic Therapy Attempts on Livedoid Vasculopathy: A Report of Case Series
Fei Qi,Yimeng Gao,Hongzhong Jin
DOI: https://doi.org/10.2147/ccid.s455903
2024-05-09
Clinical Cosmetic and Investigational Dermatology
Abstract:Fei Qi, Yimeng Gao, Hongzhong Jin Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, 100730, People's Republic of China Correspondence: Hongzhong Jin, Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases and Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, 100730, People's Republic of China, Tel +86-10-69151500, Email The application of biologics such as anti-tumor necrosis factor (TNF) has shown great efficacy in livedoid vasculopathy (LV). However, new biological options need to be identified for those with a high tuberculosis reactivation risk. In this study, we evaluated the efficacy of anti-17A biologics for LV therapy. Two patients with LV who were irresponsive to traditional anticoagulation therapy were studied at the outpatient dermatology clinic of Peking Union Medical College Hospital. All patients received anti-17A biological therapy for at least two–four weeks. Both patients reported an exacerbation of the skin lesions, which might indicate that the IL-17 pathway plays a critical role in LV pathogenesis. Keywords: livedoid vasculopathy, biologic therapy, TNF-alpha, IL-17, atrophied blanched Livedoid vasculopathy (LV) is a rare condition characterized by extensive patterns of discolored skin (livedo reticularis), pigmented purpuric dermatosis-like lesions, painful ulcers, and scar tissue with a silvery appearance. 1 Microscopically, it is marked by focal microvascular thrombosis within the lumina without a significant inflammatory infiltrate. 2 However, the pathogenesis of LV remains unclear. Recent studies have revealed hypercoagulability, encompassing microcirculatory and thrombotic events, with an inflammatory mechanism having a supporting role. 1 Most patients with LV demonstrate recurrent episodes and exacerbations, especially during summer. The agonizing ulcers caused great pain, which severely lowered the patients' quality of life and immobilized a few patients. 3 There are no first-line or standard treatment for livedoid vasculopathy has been found. Currently, the most popular treatment option for livedoid vasculopathy is anticoagulant monotherapy such as rivaroxaban. A certain degree of curative effect has been observed for other treatments of livedoid vasculopathy, including vitamin supplementation, UV light, thrombolytics, intravenous immunoglobulins, anabolic steroids, and combination therapy. 4 Introduction of biologics has shed light on most chronic dermatological diseases. In a previous study, we found that using anti-tumor necrosis factor (TNF) medications in combination with anticoagulants had a significant positive impact on resolving LV lesions and managing pain in patients with uncontrolled LV ulcers. 5 However, for individuals at high risk of tuberculosis reactivation or those who do not respond well to anti-TNF therapy, we are still searching for more effective treatment options. Studies have reported that inhibition of TNF alpha partially limits the pro-coagulative effect of IL-17A that confers in other autoimmune diseases the higher cardiovascular risk. 6 In this report, we present two cases of LV that did not respond to standard treatments and worsened after receiving anti-17A biological treatment (Table 1). The study was approved by the Ethics Committee of Peking Union Medical College Hospital. Written informed consent for publication was obtained from two patients. Table 1 Patient Characteristics and Response to Anti-17A Therapy A 41-year-old male, previously in good health, presented with recurring painful ulcers on his lower limbs and feet during the summer months over a span of 7 years. He was diagnosed as livedoid vasculopathy by his clinical appearance and the further confirmed the diagnosed by both skin biopsy and the recommended diagnostic pathway. 2 He experienced significant improvement in symptoms during the summer when he began taking a daily dose of 30 mg prednisone, which was later tapered to a maintenance dose of 10 mg. Unfortunately, in summer, his condition deteriorated, and prednisone therapy at 30 mg had a minimal impact. To alleviate the symptoms, an additional 10 mg of rivaroxaban was administered, resulting in partial relief from pain, although a few new ulcers emerged (Figure 1). Figure 1 Patient in Case 1 before Secukinumab 300mg treatment. During his visit, he complained of recent cough. We ordered a CT scan that demonstrated s -Abstract Truncated-
dermatology